Funding for this research was provided by:
National Institute on Aging (1P30-AG062429-01)
Received: 11 July 2020
Accepted: 29 August 2020
First Online: 10 September 2020
Ethics approval and consent to participate
: For submission of data to the NACC, each local institutional review board approved the research protocol and written informed consent was obtained from each participant or participant’s guardian.
: Not applicable.
: Dr. Brewer has served on advisory boards for Elan, Bristol-Myers Squibb, Avanir, Novartis, Genentech, and Eli Lilly and holds stock options in CorTechs Labs, Inc. and Human Longevity, Inc.